B · Normal
[Baili Tianheng: Received the second milestone payment of US$250 million from BMS] On November 17, Baili Tianheng (688506.SH) announced that the company’s wholly-owned subsidiary SystImmune recently received the second milestone payment of US$250 million from Bristol-Myers Squibb. To date, the company has received a total of US$1.3 billion in payments under the cooperation agreement. Under the agreement, the company is also eligible to receive additional payments of up to $7.1 billion upon reaching certain development, registration and sales milestones.
Comments